Latest news and press releases about Cocrystal Pharma, Inc. (COCP): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses.
Price
| Price | $1.14 |
| Market Cap | $16M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 14.67 |
| EV / EBITDA | -1.55 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -207.47% |
| Return on Invested Capital | -423.90% |
| Return on Assets | -213.77% |
| Gross Margin | 205.76% |
| Operating Margin | -3063.64% |
| Net Margin | -3011.52% |
Related companies: BOLT · BRTX · CING · DWTX · EVGN · IMNN · IMRN
Explore sector: Healthcare · Biotechnology
More sections of COCP: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks